Oct 12 2010
Accuray Incorporated has declared that its CyberKnife Robotic Radiosurgery, a non-invasive robotic technique for treating tumors, has been utilized to treat the 100,000th cancer patient.
It was reported that one among four patients were offered CyberKnife radiosurgery treatment during Accuray’s financial year 2010 i.e. between July 2009 and June 2010.
For the past five years, intracranial problems like acoustic neuromas, arteriovenous malformations and brain tumors have increased globally at an average rate of 42%. In spite of this rapid increase, more than 50% of CyberKnife robotic therapies performed during Accuray's fiscal 2010 were for extracranial tumors. But this radiosurgery system can offer both intracranial and extracranial therapies.
Since CyberKnife robot can incessantly monitor and automatically treat the tumor cells found in any part of the body, it is widely employed in treating prostate and lung cancer whose corresponding global growth rates are 113% and 80% respectively. This uninterrupted growth indicates increased acceptance of CyberKnife’s exceptional efficiency by surgeons in treating cancer cells which are mobile with other physiological functions throughout the therapy.
Euan S. Thomson, President and CEO of Accuray expressed his excitement over the sustained growth in the acceptance and utilization of CyberKnife for the past few years. He said that the fiscal 2010 features a 25% growth rate of patient treatments and the increased usage of their robotic surgery clearly indicates their contribution in cancer treatment.
Source: http://www.accuray.com